Apogee Therapeutics (NASDAQ:APGE) Shares Down 6.5% – What’s Next?

Apogee Therapeutics Inc. (NASDAQ:APGE) shares dropped 6.5% during mid-day trading on Tuesday . The company traded as low as $74.21 and last traded at $74.0620. Approximately 344,728 shares traded hands during trading, a decline of 66% from the average daily volume of 1,014,072 shares. The stock had previously closed at $79.24.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: 52‑week Phase 2 Part A data showed durable maintenance and deepening responses with every‑3‑month and every‑6‑month dosing (EASI‑75 maintenance ~75% and 85%; strong vIGA results), supporting the drug’s infrequent‑dosing commercial argument. GlobeNewswire: Positive Phase 2 Part A 52‑Week Data
• Positive Sentiment: Multiple brokerages raised price targets and reiterated buy ratings (examples: Citigroup, Canaccord, Guggenheim, BTIG), signaling stronger sell‑side conviction and helping push the stock higher earlier in the session. Benzinga: Analyst Coverage
• Positive Sentiment: Buy‑side commentary and feature pieces highlight zumilokibart’s long half‑life and convenience (Q3M/Q6M) and list near‑term catalysts: Part B 16‑week induction readout in Q2 2026 and potential Phase 3 start in H2 2026. Seeking Alpha: Strong Buy / Upcoming Catalysts
• Neutral Sentiment: Management hosted/announced calls and posted detailed slides/transcripts on the 52‑week data, increasing transparency and enabling analysts to update models. Yahoo Finance: Conference Call Announcement
• Neutral Sentiment: Independent valuation commentary (Seeking Alpha) models APGE with mixed outcomes—one DCF cited ~ $73/share—highlighting that upside may depend on commercialization path, Phase 3 plans or M&A. Seeking Alpha: Valuation / DCF
• Negative Sentiment: Apogee filed a proposed $300M underwritten public offering of common stock (plus a 30‑day option for an additional $45M), which typically creates near‑term selling pressure/dilution risk and likely contributed to later weakness in the shares. GlobeNewswire: Proposed $300M Offering

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on APGE shares. Wall Street Zen lowered shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Craig Hallum reiterated a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, January 7th. BTIG Research reissued a “buy” rating and issued a $137.00 price objective on shares of Apogee Therapeutics in a research report on Monday. UBS Group upgraded Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $95.00 target price on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Apogee Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $110.43.

Apogee Therapeutics Price Performance

The business’s 50-day moving average price is $71.28 and its two-hundred day moving average price is $63.70. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of -17.33 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. Equities analysts predict that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Fairmount Funds Management Llc sold 1,750,000 shares of Apogee Therapeutics stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the completion of the transaction, the director directly owned 298,647 shares in the company, valued at approximately $22,786,766.10. This trade represents a 85.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $71.06, for a total value of $390,830.00. Following the completion of the sale, the insider directly owned 209,773 shares of the company’s stock, valued at approximately $14,906,469.38. This represents a 2.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,839,700 shares of company stock worth $140,118,083. 42.77% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently added to or reduced their stakes in APGE. Exane Asset Management acquired a new stake in shares of Apogee Therapeutics during the third quarter worth $2,048,000. JPMorgan Chase & Co. boosted its holdings in shares of Apogee Therapeutics by 57.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,137,731 shares of the company’s stock valued at $45,202,000 after buying an additional 417,161 shares during the period. Rafferty Asset Management LLC grew its position in shares of Apogee Therapeutics by 55.9% during the 3rd quarter. Rafferty Asset Management LLC now owns 65,796 shares of the company’s stock valued at $2,614,000 after buying an additional 23,585 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $1,986,000. Finally, SG Americas Securities LLC acquired a new stake in Apogee Therapeutics during the third quarter worth about $5,333,000. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.